International Journal of Hematology

DOI: 10.1007/s12185-018-2478-3 Pages: 1-12

Re-induction chemotherapy using FLAG–mitoxantrone for adult patients with relapsed acute leukemia: a single-center experience from United Arab Emirates

1. United Arab Emirates University, Department of Internal Medicine, Faculty of Medicine and Health Sciences

2. Oncology Tawam Hospital, Department of Hematology

3. Mediclinic North Wing

Correspondence to:
Inaam Bashir Hassan
Tel: 00971565774028
Email: inaambh@uaeu.ac.ae

Close

Abstract

We studied the outcome of 47 adult patients with relapsed acute leukaemia (AML = 25 and ALL = 22) treated with FLAG–mitoxantrone regimen. Median time to relapse was 10.7 months (range 1.9–27.7). Complete remission (CR2) was 60.1% which was significantly more frequent in ALL compared to AML (P = 0.049). WBC count < 100 × 109/L at initial diagnosis and time to relapse > 1 year were significantly predictor for CR2 in AML (P = 0.005 for both). Induction death was significantly higher in ALL compared to AML (P = 0.039). Median follow-up was 4.0 months (0.9–119.8) for AML and 2.1 months (range 0.6–118.1) for ALL. Nine patients underwent allogeneic stem-cell transplantation (allo-SCT). Estimated overall survival (OS) at 12 and 18 months was 60.5 and 34.6%, respectively, for AML, and 39.9 and 29.9%, respectively, for ALL. For AML patients failure to achieve CR, WBC count at initial diagnosis > 5 × 109/L and poor cytogenetic risk group was significant predictors of poor OS (P = 0.010, P = 0.025, and P = 0.015, respectively). For ALL patients failure to achieve of CR, WBC count at relapse < 5 × 109/L (CR patients) and lack of any type of consolidation therapy were significant predictor of poor OS (P < 0.001, P = 0.008, P = 0.008, respectively).

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge